Annual Report

Overview

The report describes Pacira's 2024 progress across its commercial portfolio and pipeline, including total revenues of 700,966 and two-year safety and efficacy data for PCRX-201. It also introduces the 5x30 growth strategy, focused on patient reach, product revenue, profitability, pipeline expansion, and partnerships through 2030.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: Ends 31 December 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services